Compugen to Participate in Stifel 2025 Healthcare Conference
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 04 2025
0mins
Source: PRnewswire
Company Announcement: Compugen Ltd. will participate in a fireside chat at the Stifel 2025 Healthcare Conference in New York City on November 11, 2025, from 3:20-3:50 PM ET, with a live webcast available on their website.
Company Overview: Compugen is a clinical-stage cancer immunotherapy company that uses AI/ML for drug target discovery, with two proprietary product candidates in Phase 1 development and a bispecific antibody in Phase 3 development through a partnership with AstraZeneca.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like CGEN with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on CGEN
Wall Street analysts forecast CGEN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CGEN is 4.00 USD with a low forecast of 4.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.950
Low
4.00
Averages
4.00
High
4.00
Current: 1.950
Low
4.00
Averages
4.00
High
4.00
About CGEN
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
HC Wainwright Initiates Buy on Jade Biosciences with $25 Price Target
- Rating Initiation: HC Wainwright & Co. analyst Arthur He initiated coverage on Jade Biosciences Inc (NASDAQ:JBIO) with a Buy rating and a price target of $25, reflecting confidence in the company's future growth potential.
- Market Performance: Jade Biosciences shares closed at $13.17 on Tuesday, and the analyst's target price implies an upside of over 89%, which could attract more investor interest in the stock.
- Industry Outlook: With the ongoing development in the biotech sector, Jade Biosciences' new products and technologies are expected to drive market share growth, and the positive rating may further enhance market confidence in the company.
- Investor Attention: The analyst's Buy rating and high price target could prompt more institutional investors to consider increasing their positions in the stock, thereby enhancing its liquidity and market recognition.
Continue Reading
Compugen Agrees with AstraZeneca to Monetize Future Royalties of Rilvegostomig
- Financial Strengthening: Compugen's agreement with AstraZeneca to monetize future royalties from rilvegostomig is expected to enhance its financial position, extending its cash runway into 2029 and providing ongoing support for its innovative immuno-oncology pipeline.
- Strategic Collaboration: The amended exclusive license agreement aims to bolster Compugen's capabilities in immuno-oncology, reflecting the significant potential value of rilvegostomig and further solidifying the company's market position in cancer treatment.
- Pipeline Expansion: Rilvegostomig, a PD-1/TIGIT bispecific antibody developed in collaboration with AstraZeneca, is currently in Phase 3 development, highlighting its importance in clinical trials and potential as a key future product.
- Innovative Platform Utilization: Compugen leverages its AI/ML-powered computational discovery platform (Unigen™) to identify novel drug targets, advancing the development of immunotherapies and showcasing the company's technological advantages and market potential in cancer treatment.
Continue Reading